PDCD1 and non-small cell lung carcinoma: Cantini et al. recently revealed that statin use was significantly associated with a better tumor response and longer progression-free survival (PFS) in patients with NSCLC treated with PD-1 inhibitors in an intensity-dependent manner [18].